Oakbrook Investments LLC increased its holdings in shares of Edwards Lifesciences Corporation NYSE EW by 25 7 in the third quarter according to its most recent disclosure with the SEC The firm owned 19 050 shares of the medical research company s stock after purchasing an additional 3 900 shares during the period Oakbrook Investments LLC s holdings in Edwards Lifesciences Corporation were worth 2 082 000 as of its most recent filing with the SEC A number of other institutional investors have also bought and sold shares of EW Teachers Advisors LLC grew its holdings in Edwards Lifesciences Corporation by 26 6 during the first quarter Teachers Advisors LLC now owns 835 393 shares of the medical research company s stock worth 78 585 000 after purchasing an additional 175 457 shares during the period Morgan Stanley grew its holdings in Edwards Lifesciences Corporation by 28 9 during the first quarter Morgan Stanley now owns 1 485 058 shares of the medical research company s stock worth 139 699 000 after purchasing an additional 332 671 shares during the period Renaissance Technologies LLC grew its holdings in Edwards Lifesciences Corporation by 7 1 during the first quarter Renaissance Technologies LLC now owns 926 300 shares of the medical research company s stock worth 87 137 000 after purchasing an additional 61 100 shares during the period BlackRock Inc grew its holdings in Edwards Lifesciences Corporation by 2 184 9 during the first quarter BlackRock Inc now owns 14 003 695 shares of the medical research company s stock worth 1 317 326 000 after purchasing an additional 13 390 818 shares during the period Finally KCG Holdings Inc grew its holdings in Edwards Lifesciences Corporation by 91 1 during the first quarter KCG Holdings Inc now owns 6 286 shares of the medical research company s stock worth 591 000 after purchasing an additional 2 996 shares during the period Institutional investors and hedge funds own 82 06 of the company s stock Shares of Edwards Lifesciences Corporation EW traded down 8 512 on Wednesday reaching 104 525 2 876 961 shares of the company s stock traded hands The firm has a market cap of 22 07 billion a P E ratio of 31 703 and a beta of 0 62 The company s 50 day moving average price is 111 26 and its 200 day moving average price is 112 48 Edwards Lifesciences Corporation has a one year low of 81 12 and a one year high of 121 45 Edwards Lifesciences Corporation NYSE EW last announced its quarterly earnings results on Tuesday October 24th The medical research company reported 0 84 EPS for the quarter missing the Thomson Reuters consensus estimate of 0 86 by 0 02 Edwards Lifesciences Corporation had a net margin of 22 16 and a return on equity of 27 17 The firm had revenue of 821 50 million during the quarter compared to the consensus estimate of 833 85 million During the same period in the previous year the business earned 0 68 earnings per share The firm s revenue for the quarter was up 11 1 on a year over year basis On average equities analysts forecast that Edwards Lifesciences Corporation will post 3 78 EPS for the current fiscal year In other Edwards Lifesciences Corporation news VP Donald E Bobo Jr sold 5 300 shares of the firm s stock in a transaction on Friday July 28th The shares were sold at an average price of 114 68 for a total value of 607 804 00 The sale was disclosed in a filing with the Securities Exchange Commission which is available through this hyperlink Also VP Larry L Wood sold 18 960 shares of the firm s stock in a transaction on Monday October 16th The shares were sold at an average price of 108 54 for a total transaction of 2 057 918 40 The disclosure for this sale can be found here Over the last three months insiders sold 201 161 shares of company stock valued at 22 826 072 Insiders own 2 13 of the company s stock A number of equities analysts recently commented on EW shares SunTrust Banks Inc lifted their price target on Edwards Lifesciences Corporation to 14 00 and gave the stock a buy rating in a report on Monday July 17th Jefferies Group LLC reiterated a buy rating and set a 115 00 price target on shares of Edwards Lifesciences Corporation in a report on Friday June 30th Canaccord Genuity reiterated a buy rating and set a 150 00 price target on shares of Edwards Lifesciences Corporation in a report on Wednesday June 28th Royal Bank Of Canada reiterated a buy rating and set a 130 00 price target on shares of Edwards Lifesciences Corporation in a report on Friday July 28th Finally Stifel Nicolaus reiterated a buy rating and set a 130 00 price target up previously from 118 00 on shares of Edwards Lifesciences Corporation in a report on Thursday July 27th Seven research analysts have rated the stock with a hold rating fifteen have issued a buy rating and one has issued a strong buy rating to the company s stock The company currently has a consensus rating of Buy and an average price target of 119 79 WARNING Edwards Lifesciences Corporation EW Shares Bought by Oakbrook Investments LLC was posted by StockNewsTimes and is the property of of StockNewsTimes If you are reading this story on another publication it was illegally copied and republished in violation of U S and international copyright and trademark laws The original version of this story can be viewed at https stocknewstimes com 2017 10 25 edwards lifesciences corporation ew shares bought by oakbrook investments llc html Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient s diseased or defective heart valve The Company is engaged in patient focused innovations for structural heart disease and critical care monitoring Its segments include United States Europe Japan and Rest of World Receive News Ratings for Edwards Lifesciences Corporation Daily Enter your email address below to receive a concise daily summary of the latest news and analysts ratings for Edwards Lifesciences Corporation and related companies with MarketBeat com s FREE daily email newsletter